Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888222 | 0.92 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1POLA1MEN1 | |
| SCHEMBL888285 | 0.78 | TAS1R3 (0.47) | KDM4ETAS1R3TAS1R1POLA1MEN1 | |
| SCHEMBL889582 | 0.74 | SLC29A1 (0.34) | KDM4E | |
| SCHEMBL14789029 | 0.74 | SLC29A1 (0.34) | KDM4E | |
| SCHEMBL14789009 | 0.74 | KDM4E (0.53) | KDM4ETAS1R3TAS1R1POLA1MEN1 | |
| SCHEMBL889631 | 0.74 | KDM4E (0.53) | KDM4ETAS1R3TAS1R1POLA1MEN1 | |
| SCHEMBL12762713 | 0.73 | SLC29A1 (0.33) | KDM4E | |
| SCHEMBL12570255 | 0.73 | SLC29A1 (0.33) | KDM4E | |
| SCHEMBL12762706 | 0.72 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1POLA1MEN1 | |
| SCHEMBL12570240 | 0.72 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1POLA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125856-B1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | KDM4E 4303/4885TAS1R3 1740/4885TAS1R1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.